ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: FASEB Report On Diet and Cancer Mortality Available; Don Poppke AO of Nursing Center

March 6, 1987

ONS Plans One Day Course On Nursing Research

November 11, 1988

New International Policy On Clinical Trials Is Needed, Veronesi Says

October 21, 1983

BCI Budget Chief Browning To Retire

January 12, 1979

In Brief: Pelayo Correa Heads LSU Cancer Center; Foundation to Honor Feinstein, Mack

September 5, 1997

Scope Of Panel’s Inquiry Outlined In Letter To Members

July 22, 1994